Associate Professor, Surgery, Oregon Health and Science University School of Medicine
Urology
Dr. Mark G. Garzotto, MD
|
|
Give Review
Mark Garzotto is an expert in the field of Urology. He attended Louisiana State University School of Medicine in New Orleans. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Mark G. Garzotto, MD is a published physician. He has 59 publications published. The most current publication "Primary primitive neuroectodermal tumor of the kidney. Case report and review of the literature."
Publications
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate Cancer.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- Agent Orange as a risk factor for high-grade prostate Cancer.
- Advances in the Multimodality Management of High-risk Prostate Cancer.
- Feasibility of shutter-speed DCE-MRI for improved prostate Cancer detection.
- Chemotherapy-induced monoamine oxidase expression in Prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
- Primary primitive neuroectodermal tumor of the Kidney. Case report and review of the literature.
- Multimodal therapy for neoplasms arising from a vesical diverticulum.
- Closure of laparoscopic trocar sites using a spring-loaded needle.
- Uric acid stone and gastric Bladder augmentation.
- Androgen deprivation therapy for prostate Cancer: not so simple.
- Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate Cancer.
- Minimal benefit of an endorectal balloon for Prostate immobilization as verified by daily localization.
- Acupuncture for hot flashes in patients with prostate Cancer.
- Contemporary management of high-risk localized prostate Cancer.
- ID1 enhances docetaxel cytotoxicity in prostate Cancer cells through inhibition of p21.
- Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate Cancer.
- Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate Cancer.
- CCL2 is induced by chemotherapy and protects prostate Cancer cells from docetaxel-induced cytotoxicity.
- Folate intake and prostate Cancer risk: a case-control study.
- Prostate Cancer-associated gene expression alterations determined from needle biopsies.
- Lower Urinary tract symptoms increase the risk of falls in older men.
- A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate Cancer.
- Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after Prostatectomy, a phase III randomized study of Prostatectomy versus Prostatectomy with adjuv...
- Molecular alterations in Prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differ...
- Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate Cancer.
- Assessment of prostate-specific antigen doubling time in prediction of prostate Cancer on needle biopsy.
- Predictors of overall and Cancer-free survival of patients with localized prostate Cancer treated with primary androgen suppression therapy: results from the prostate ...
- Parenteral estrogens for prostate Cancer: can a new route of administration overcome old toxicities?
- Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with Cancer.
- Metastatic adenocarcinoma of Prostate in a healing sternotomy site.
- Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tum...
- Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate Cancer.
- Effect of calcitriol on Prostate-specific antigen in vitro and in humans.
- Classification and regression tree analysis for the prediction of aggressive prostate Cancer on biopsy.
- Testosterone loss and estradiol administration modify memory in men.
- Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate Cancer.
- Recursive partitioning for risk stratification in men undergoing repeat Prostate biopsies.
- Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate Cancer.
- High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate Cancer: a phase I/II study.
- Statins and prostate Cancer risk: a case-control study.
- Resistance of prostate Cancer cell lines to COX-2 inhibitor treatment.
- Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate Cancer.
- Improved detection of prostate Cancer using classification and regression tree analysis.
- Radical retropubic Prostatectomy after orthotopic liver transplantation.
- Phase II study of transdermal estradiol in androgen-independent Prostate carcinoma.
- Randomized study of high-dose pulse calcitriol or placebo prior to radical Prostatectomy.
- High-dose calcitriol and carboplatin in metastatic androgen-independent prostate Cancer.
- Predictors of delayed therapy after expectant management for localized prostate Cancer in the era of prostate-specific antigen.
- Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate Cancer.
- Targeting FSH in androgen-independent prostate Cancer: abarelix for prostate Cancer progressing after orchiectomy.
- Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent Prostate carcinoma.
- Predictive modeling for the presence of Prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with Prostate specific antigen levels < or...
- A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate Cancer.
- Phase II study of abarelix depot for androgen independent prostate Cancer progression during gonadotropin-releasing hormone agonist therapy.
- Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate Cancer.
Schools
Louisiana State Univ School Of Medicine In New Orleans
University Of Fl College Of Med
Procedures Preformed
- Adrenalectomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Kidney and Ureter Removal
- Prostate Removal
- View All
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Elevated PSA (Prostate Specific Antigen)
- View All
Doctors Specialties
- Urology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Choice Health PPO
- First Health (Coventry Health Care) PPO
- Health Plan of Oregon PPO
- ODS Health Plan
- Preferred PSN
- Heritage Plus
- Heritage Signature
- Preferred PPO
- Preferred Provider Network PPN
- Choice Plus POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Florida -
Louisiana State University School of Medicine in New Orleans
Helpful Reviews
Similar Doctors
|
|
Dr. Nicholas N. Tadros, MD |
|
|
Dr. Robert E. Barham, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley A. Myers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel M. Janoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen R. Dunn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clifford O. Stranburg, MD |
|
|
Dr. Daniel E. Swanson, MD |
|
|
Dr. Serena Z. Yang, MD |
|
|
Dr. Jonathan L. Witten, MD |